ATE471720T1 - Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73 - Google Patents

Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73

Info

Publication number
ATE471720T1
ATE471720T1 AT04721913T AT04721913T ATE471720T1 AT E471720 T1 ATE471720 T1 AT E471720T1 AT 04721913 T AT04721913 T AT 04721913T AT 04721913 T AT04721913 T AT 04721913T AT E471720 T1 ATE471720 T1 AT E471720T1
Authority
AT
Austria
Prior art keywords
cytokine
induced expression
adenosine levels
increasing adenosine
increasing
Prior art date
Application number
AT04721913T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20030467A external-priority patent/FI20030467A0/fi
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Application granted granted Critical
Publication of ATE471720T1 publication Critical patent/ATE471720T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT04721913T 2003-03-28 2004-03-19 Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73 ATE471720T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20030467A FI20030467A0 (fi) 2003-03-28 2003-03-28 Menetelmä tulehdustilojen hoitamiseen
US51542503P 2003-10-30 2003-10-30
PCT/FI2004/000158 WO2004084933A1 (en) 2003-03-28 2004-03-19 Elevation of adenosine level by cytokine-induced expression of cd73

Publications (1)

Publication Number Publication Date
ATE471720T1 true ATE471720T1 (de) 2010-07-15

Family

ID=33099764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04721913T ATE471720T1 (de) 2003-03-28 2004-03-19 Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73

Country Status (9)

Country Link
US (3) US7534423B2 (de)
EP (1) EP1608400B1 (de)
JP (1) JP2011225607A (de)
AT (1) ATE471720T1 (de)
CA (1) CA2519465C (de)
CY (1) CY1111215T1 (de)
DE (1) DE602004027797D1 (de)
PL (1) PL1608400T3 (de)
WO (1) WO2004084933A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160645A1 (en) * 2001-10-25 2007-07-12 Jakob Vinten-Johansen PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs
ES2316618T3 (es) 2001-10-25 2009-04-16 Emory University Cateter para perfusion modificada.
WO2006069170A2 (en) * 2004-12-22 2006-06-29 Emory University Therapeutic adjuncts to enhance the organ protective effects of postconditioning
ATE471720T1 (de) 2003-03-28 2010-07-15 Faron Pharmaceuticals Oy Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
FI20070795A0 (fi) * 2007-10-24 2007-10-24 Faron Pharmaceuticals Oy Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
US8975081B2 (en) * 2007-10-24 2015-03-10 Faron Pharmaceuticals Oy Biomarker for monitoring development of diseases and assessing the efficacy of therapies
US20090130092A1 (en) 2007-10-30 2009-05-21 Pinsky David J Nucleotide phosphate dissipation as a treatment for vascular disorders
WO2009106368A1 (en) * 2008-02-29 2009-09-03 Gelato Corporation N.V. Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases
CN102014959B (zh) * 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
IN2012DN02753A (de) 2009-08-31 2015-09-18 Amplimmune Inc
CN107441480A (zh) 2010-06-30 2017-12-08 卡姆普根有限公司 多肽及其作为用于治疗多发性硬化、类风湿性关节炎以及其他自身免疫病症的药物的用途
CU23963B1 (es) * 2011-07-01 2013-12-11 Ct De Ingeniería Genética Y Biotecnología Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
WO2013040552A2 (en) 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
EP2934575A2 (de) 2012-12-19 2015-10-28 Amplimmune, Inc. B7-h4-spezifische antikörper sowie zusammensetzungen und verfahren zur verwendung davon
ES2957882T3 (es) 2015-09-04 2024-01-29 Univ Yale Nanocomposiciones de ácidos biliares poliméricos dirigidas al páncreas y al colon
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof
WO2017155981A1 (en) 2016-03-07 2017-09-14 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
RU2757394C2 (ru) 2016-08-03 2021-10-14 Нексткьюр, Инк. Композиции и способы для модуляции передачи сигнала lair
EP4360714A2 (de) 2016-09-21 2024-05-01 Nextcure, Inc. Antikörper für siglec-15 und verfahren zur verwendung davon
US11390675B2 (en) 2016-09-21 2022-07-19 Nextcure, Inc. Antibodies for Siglec-15 and methods of use thereof
AU2018329840A1 (en) 2017-09-07 2020-03-19 Augusta University Research Institute, Inc. Specific Akt3 activator and uses thereof
EP3911302A1 (de) 2019-01-17 2021-11-24 Georgia Tech Research Corporation Arzneimittelabgabesysteme mit oxidierten cholesterinen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341369C (en) * 1985-10-14 2002-06-18 Michel Revel Human interferon-.beta.2a and interferon-.beta.2b; vectors containing genes coding for said interferons: cell lines producing same and use of said interferons as pharmaceuticals
GB9702021D0 (en) * 1997-01-31 1997-03-19 Imperial College Medicaments
EP1221976A4 (de) * 1999-09-28 2003-12-03 Amarillo Biosciences Inc Ifn-gama in niedriger dosierung zur behandlung von erkrankungen
DE60129472T2 (de) 2001-04-03 2008-04-17 U-Cytech B.V. Behandlung von hypoxya/ischaemia blutflusswiderstand mit beta-interferon
WO2002089828A2 (en) 2001-05-04 2002-11-14 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
US6911198B2 (en) 2001-09-17 2005-06-28 Yeda Research And Development Co. Ltd. Method and pharmaceutical composition for treating inflammation
WO2003075944A2 (en) 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
ATE471720T1 (de) 2003-03-28 2010-07-15 Faron Pharmaceuticals Oy Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73

Also Published As

Publication number Publication date
US20090269303A1 (en) 2009-10-29
JP2011225607A (ja) 2011-11-10
CA2519465A1 (en) 2004-10-07
PL1608400T3 (pl) 2010-11-30
WO2004084933A1 (en) 2004-10-07
EP1608400A1 (de) 2005-12-28
US7534423B2 (en) 2009-05-19
US20060198821A1 (en) 2006-09-07
US7727521B2 (en) 2010-06-01
CA2519465C (en) 2016-08-02
EP1608400B1 (de) 2010-06-23
DE602004027797D1 (de) 2010-08-05
US20060034801A1 (en) 2006-02-16
CY1111215T1 (el) 2015-06-11

Similar Documents

Publication Publication Date Title
ATE471720T1 (de) Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73
ATE427356T1 (de) Komplementinhibitoren aus zecken
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
WO2006110187A3 (en) Methods and compositions for the treatment of anxiety disorders
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
TW200716612A (en) Pyrimidine compounds
DOP2007000051A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
PA8649201A1 (es) Composiciones fungicidas
AR060089A1 (es) Tratamiento del dolor
MX2009007644A (es) Compuestos de piperidina heterociclicos sustituidos y usos de los mismos.
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
BRPI0607850A2 (pt) método para o tratamento de materiais contendo cobre
DK1965809T3 (da) Præparater til forbedring af sundhedstilstanden i dyrs tarmsystem og dyrs ydeevne omfattende Beta-glucanerne og Alfa-fucaner
DE60333901D1 (de) Verfahren zur reduzierung der angiogenese
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
TW200742580A (en) Methods for treating nephrolithiasis
IN2015DN03331A (de)
NO20092018L (no) Fremgangsmater for a behandle depresjon
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
TW200500079A (en) Compositions and methods for treating coronavirus infection and sars
WO2009108252A3 (en) Method for stimulating immune response against moraxella catarrhalis
CL2004000765A1 (es) Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.
BR112014014805A2 (pt) processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1608400

Country of ref document: EP